Amprolium (Corid / Amprol)

Amprolium is an anticoccidial drug used extensively in livestock and poultry for the prevention and treatment of coccidiosis, a parasitic intestinal disease caused by protozoan organisms of the genus Eimeria. Sold under the brand names Corid, Amprol, Amprid, and CocciAid, amprolium has been a mainstay of coccidiosis management in agricultural settings for decades. Unlike antibiotics, amprolium is not bactericidal or bacteriostatic - it is a structural analogue of thiamine (vitamin B1) that exploits the metabolic dependence of Eimeria parasites on thiamine uptake. This unique mechanism of action gives amprolium a favorable safety profile, low residue potential, and minimal impact on the beneficial gut microbiota of treated animals.

The chemical structure of amprolium closely resembles that of thiamine, allowing it to compete for the thiamine transporter systems on the surface of Eimeria organisms. When coccidia absorb amprolium instead of thiamine, their intracellular carbohydrate metabolism is disrupted because thiamine serves as an essential cofactor for key enzymes in the citric acid cycle and pentose phosphate pathway. Without functional thiamine-dependent metabolism, the parasites cannot generate the energy required for growth and reproduction, and their development is arrested during the schizogony stages - the asexual reproductive phase in which coccidia multiply most aggressively within the intestinal epithelium. This targeted interference with parasite metabolism, rather than direct killing, classifies amprolium as a coccidiostat rather than a coccidiocide.

Amprolium is FDA-approved for use in cattle and poultry in the United States, and it is available over the counter without a prescription. In cattle, the labeled indication covers the treatment and prevention of coccidiosis caused by Eimeria bovis and Eimeria zurnii in calves. In poultry, amprolium is approved for the prevention and treatment of coccidiosis caused by multiple Eimeria species and is notably one of the few anticoccidial products approved for use in laying hens without an egg withdrawal period. The drug is also widely used extra-label in goats, sheep, rabbits, and camelids under veterinary guidance, reflecting its broad utility across species susceptible to Eimeria infections.

From a practical standpoint, amprolium is favored by producers for several reasons beyond its efficacy. The drug has an extremely low toxicity profile in mammalian and avian hosts because the thiamine transport systems of host intestinal cells are far less permeable to amprolium than those of Eimeria organisms. Approximately 97 percent of an administered dose is excreted unchanged, resulting in minimal tissue residue accumulation and short withdrawal periods. Amprolium also generates relatively few resistance problems compared to ionophore coccidiostats and sulfonamide drugs, and it is compatible with most feed additives and vitamin supplements used in livestock production, with the notable exception of supplemental thiamine, which can antagonize its anticoccidial effect.

The primary indication for amprolium in cattle is the treatment and prevention of bovine coccidiosis caused by Eimeria bovis and Eimeria zurnii. These two species are the most pathogenic bovine Eimeria, responsible for the clinical syndrome commonly known as bloody scours in calves. Bovine coccidiosis is most prevalent in young calves between three weeks and six months of age, and outbreaks typically occur during periods of environmental stress such as weaning, shipping, crowding in feedlots, and inclement weather. Subclinical infections are equally important because they impair feed conversion, suppress weight gain, and create a reservoir of environmental contamination that perpetuates the cycle of infection within a herd. Amprolium addresses both the clinical disease through its five-day treatment protocol and subclinical exposure through its 21-day prevention protocol.

In poultry, amprolium is indicated for the prevention and treatment of coccidiosis caused by multiple Eimeria species, including E. tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and E. mitis in chickens, and E. adenoides, E. gallopavonis, and E. meleagrimitis in turkeys. Coccidiosis is among the most economically significant diseases in commercial poultry production, causing mortality, morbidity, reduced growth rates, and impaired feed efficiency. Amprolium occupies a unique position in poultry medicine as the only active pharmaceutical ingredient approved by the FDA for both prevention and treatment of coccidiosis in laying chickens, with no withdrawal requirement for eggs when used at labeled doses. This makes it the product of choice for managing coccidiosis outbreaks in egg-producing flocks where other anticoccidials would require egg withdrawal or are not approved for layers.

Extra-label applications of amprolium extend to several species not covered by the FDA-approved labeling. In goats and sheep, amprolium is commonly used to treat and prevent coccidiosis caused by species such as Eimeria arloingi, E. christenseni, and E. ninakohlyakimovae in goats, and E. ovinoidalis and E. crandallis in sheep. Young kids and lambs are particularly susceptible to coccidiosis during the stress of weaning and environmental transition, and amprolium administered in drinking water or as an oral drench provides a practical treatment option. In rabbits, amprolium is used against both intestinal coccidiosis caused by species like E. magna and E. perforans and hepatic coccidiosis caused by E. stiedae, though hepatic infections may require extended treatment courses of 10 to 14 days. Camelids, including llamas and alpacas, are treated extra-label for Eimeria macusaniensis infections, which can cause severe and sometimes fatal enteritis.

The strategic use of amprolium in production settings reflects an understanding of the Eimeria life cycle and the conditions that trigger clinical disease. Producers use amprolium prophylactically during high-risk periods - the first weeks after arrival in a feedlot, the brooding period in poultry houses, the post-weaning transition in calves and small ruminants - when stress suppresses immunity and environmental oocyst loads are highest. This preventive approach, administered at lower doses over a longer duration, limits parasite multiplication enough to prevent clinical disease while still allowing some low-level exposure that stimulates the development of natural immunity. The balance between suppressing disease and permitting immunity development is one of the key advantages of amprolium compared to more potent coccidiocides that eliminate parasites so completely that animals fail to develop protective immunity.

Amprolium is administered orally through three delivery methods: medicated drinking water, individual oral drench, and feed top-dress using the crumble formulation. The choice of delivery method depends on the species being treated, the number of animals involved, and the clinical situation. Medicated drinking water is the most common method for treating groups of calves or flocks of poultry, while oral drenching provides more precise dosing for individual animals or valuable livestock where accurate intake must be ensured. The crumble formulation offers a convenient feed-based delivery system for cattle operations where water medication equipment is not available.

For bovine coccidiosis treatment using the 9.6% oral solution, the labeled protocol calls for adding 16 fluid ounces of Corid 9.6% solution per 100 gallons of drinking water, which delivers approximately 10 milligrams of amprolium per kilogram of body weight at normal water consumption rates. This treatment concentration is offered as the sole water source for five consecutive days. When treating individual calves by drench, three fluid ounces of the 9.6% solution are added to one pint of water, and one fluid ounce of this drench mixture is administered per 100 pounds of body weight daily for five days. For prevention during periods of anticipated coccidiosis exposure, the dose is reduced to approximately 5 milligrams per kilogram per day - achieved by adding 8 fluid ounces of the 9.6% solution per 100 gallons of drinking water - and is administered for 21 consecutive days.

The 20% soluble powder formulation follows a parallel dosing structure. For the five-day treatment program, one 10-ounce packet is dissolved in 125 gallons of drinking water, providing approximately 10 milligrams of amprolium per kilogram of body weight at normal consumption. For the 21-day prevention program, one 10-ounce packet is dissolved in 250 gallons of drinking water, delivering approximately 5 milligrams per kilogram. The 1.25% crumble formulation is fed as a top-dress on calf rations at 0.40 pounds per 500 pounds of body weight for the five-day treatment program, or 0.20 pounds per 500 pounds of body weight for the 21-day prevention program. Regardless of formulation, medicated water or feed must be prepared fresh daily, and amprolium should be the sole source of the active ingredient during the treatment period.

Poultry dosing follows species-specific label directions that vary by the particular product and formulation. In general, drinking water concentrations of approximately 125 parts per million of amprolium are used for prevention in broiler and layer flocks, with higher concentrations used for active treatment of clinical outbreaks. Treatment duration typically ranges from five to seven days for therapeutic protocols and may extend to several weeks for preventive programs during the brooding period. In laying flocks, the labeled preventive dose can be administered continuously without an egg withdrawal requirement, which is a significant advantage over other anticoccidial products.

For extra-label use in goats, sheep, and rabbits, dosing is typically guided by veterinary consultation and extrapolated from the bovine and poultry label directions. Goats and sheep are commonly treated at approximately 10 milligrams per kilogram per day for five days for active coccidiosis, or 5 milligrams per kilogram per day for 21 days for prevention, following the same dose-duration principles established for cattle. Fresh medicated water should be prepared daily for all species, and producers should ensure that animals are consuming adequate quantities of the medicated water, as sick or dehydrated animals may drink too little to receive a therapeutic dose. In such cases, individual drenching ensures accurate dosing.

Amprolium exerts its anticoccidial effect through competitive inhibition of thiamine uptake by Eimeria parasites. The drug's molecular structure mimics that of thiamine so closely that it is recognized and transported by the same carrier proteins that Eimeria organisms use to import thiamine from the host intestinal environment. Once amprolium occupies these transporters, genuine thiamine cannot enter the parasite cell in sufficient quantities to support normal metabolic function. This competitive antagonism is concentration-dependent: as the ratio of amprolium to thiamine in the intestinal lumen increases, the proportion of transporter activity diverted to amprolium rises, and the parasite's effective thiamine supply diminishes accordingly.

Thiamine is an essential cofactor for several enzymes in the carbohydrate metabolism pathways that Eimeria species depend upon for energy production. Specifically, thiamine pyrophosphate - the active form of thiamine - is required by pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase, enzymes central to the citric acid cycle and the pentose phosphate pathway. When amprolium depletes intracellular thiamine stores in Eimeria organisms, these metabolic pathways are disrupted, and the parasites cannot synthesize the adenosine triphosphate needed for growth, replication, and completion of their intracellular life cycle. The effect is most pronounced during the first and second generation schizogony stages, when the parasites are multiplying rapidly within intestinal epithelial cells and have the highest metabolic demands.

The selectivity of amprolium for parasite thiamine transport over host thiamine transport is what gives the drug its wide margin of safety. Mammalian and avian intestinal epithelial cells absorb thiamine through transport mechanisms that have substantially lower affinity for amprolium than the corresponding systems in Eimeria organisms. As a result, at therapeutic doses, amprolium effectively starves the parasites of thiamine while leaving the host's thiamine supply largely unaffected. This differential affinity is not absolute, however, and at high doses or with prolonged administration, amprolium can interfere with host thiamine metabolism sufficiently to produce clinical signs of thiamine deficiency - a risk that establishes the upper boundary of safe dosing.

An important pharmacological characteristic of amprolium is that it is coccidiostatic rather than coccidiocidal. The drug arrests parasite development and prevents the explosive multiplication that causes clinical disease, but it does not kill all parasites outright. This property has a practical advantage in livestock production: low-level parasite survival during amprolium treatment allows the host immune system to encounter Eimeria antigens and develop protective immunity. Animals that are treated with amprolium during their first exposure to coccidiosis typically develop stronger natural resistance than animals treated with drugs that eliminate parasites so thoroughly that the immune system never encounters them. This balance between disease control and immunity development makes amprolium particularly well-suited for young animals experiencing their first coccidial challenge.

Amprolium has one of the widest safety margins of any anticoccidial drug in veterinary medicine, reflecting the selectivity of its mechanism of action for parasite thiamine transport over host thiamine transport. At labeled doses, adverse effects in cattle and poultry are rare, and the drug is generally well tolerated even in young, stressed, or debilitated animals - precisely the population most likely to require treatment. The most commonly reported reactions at therapeutic doses are mild and transient, including temporary changes in water or feed consumption patterns that typically resolve within the first day or two of treatment.

The most significant toxicological concern with amprolium is the potential for thiamine deficiency when the drug is administered at excessive doses or for prolonged periods beyond label recommendations. Because amprolium competes with thiamine at the host level - albeit with much lower affinity than at the parasite level - overdosing can deplete host thiamine stores to the point where clinical deficiency develops. In cattle, thiamine deficiency manifests as polioencephalomalacia, a neurological syndrome characterized by blindness, incoordination, head pressing, opisthotonus, and seizures. In poultry, thiamine deficiency produces polyneuritis with leg weakness, head retraction (stargazing), and paralysis. These effects are dose-dependent and time-dependent, occurring at multiples of the recommended dose or with treatment durations substantially exceeding label recommendations. The narrow margin for error at high doses underscores the importance of accurate dosing calculations and strict adherence to labeled treatment durations.

Drug interactions with amprolium are limited but clinically important. The most significant interaction is with supplemental thiamine (vitamin B1): administering thiamine concurrently with amprolium directly antagonizes the drug's anticoccidial activity by increasing the thiamine-to-amprolium ratio in the intestinal lumen, allowing parasites to access sufficient thiamine despite amprolium's competitive inhibition. For this reason, thiamine supplementation should be withheld during active amprolium treatment, and vitamin premixes containing B1 should be removed from feed during the treatment period. Conversely, thiamine administration is the specific antidote for amprolium toxicity: if signs of thiamine deficiency develop during treatment, parenteral thiamine at 10 to 20 milligrams per kilogram reverses the neurological effects rapidly. Amprolium should also not be administered concurrently with high levels of choline, as interactions between the two compounds have been reported.

Amprolium does not suppress the formation of anticoccidial immunity to the same degree as more potent coccidiocides, but its coccidiostatic action does partially modulate the immune response to Eimeria exposure. Animals treated with amprolium during initial coccidial challenge develop immunity, but this immunity may develop more slowly or to a lower peak level than in animals that experience untreated, self-limiting infections. This consideration is most relevant in production systems that rely on early natural exposure to build flock or herd immunity, where the timing and duration of amprolium use should be balanced against the need for robust immunity development. In most practical settings, the disease prevention benefits of amprolium treatment substantially outweigh any reduction in the rate of immunity acquisition.

Withdrawal times for amprolium are among the shortest of any livestock medication, reflecting the drug's rapid excretion and minimal tissue accumulation. For cattle treated with the 9.6% oral solution or 20% soluble powder formulations, the FDA-approved label specifies a 24-hour withdrawal period before slaughter. This means that treated cattle must not be slaughtered for human consumption within 24 hours of the last amprolium dose. A withdrawal period has not been established for pre-ruminating calves, and the labeling specifically states that amprolium should not be used in calves destined for veal processing. These restrictions reflect the limited pharmacokinetic data available for very young calves whose metabolic clearance pathways may differ from those of older, ruminating animals.

For poultry, the withdrawal situation varies by product and labeled use. Amprolium is unique among anticoccidial drugs in that certain formulations approved for laying chickens carry zero egg withdrawal when used at the labeled preventive dose. This means that eggs from hens receiving amprolium at prevention-level concentrations can be collected and sold for human consumption without any withholding period. For meat birds, withdrawal times vary by product but are generally short - typically zero to 24 hours for products specifically labeled for broilers. The absence of prolonged withdrawal requirements makes amprolium particularly practical for managing coccidiosis outbreaks in commercial egg and broiler operations where production interruptions carry significant economic consequences.

The pharmacokinetic basis for these short withdrawal times lies in the way amprolium is handled by the body. Approximately 97 percent of an administered dose is excreted unchanged, primarily through the feces. The drug does not undergo extensive hepatic metabolism, does not accumulate in fat or muscle tissue, and does not bind significantly to tissue proteins. These characteristics mean that amprolium clears from edible tissues rapidly after the last dose, and residue levels in meat, organs, and eggs fall below detectable limits within hours of cessation of treatment. Regulatory tolerance levels established by the FDA for amprolium residues in cattle tissues reflect this favorable residue profile.

For extra-label uses in species such as goats, sheep, and rabbits, no official withdrawal times have been established by the FDA because these applications fall outside the scope of the approved labeling. Veterinarians prescribing amprolium extra-label in food-producing animals are required by the Animal Medicinal Drug Use Clarification Act to establish extended withdrawal times that provide reasonable assurance of residue safety. Common recommendations for extra-label withdrawal in small ruminants range from seven to ten days before slaughter, though specific guidance should be obtained from the prescribing veterinarian. For rabbits raised for meat, a withdrawal period of at least five days is commonly recommended. Producers using amprolium extra-label should maintain accurate treatment records including dates, doses, and withdrawal period calculations to comply with regulatory requirements and food safety standards.

Coccidiosis is a parasitic disease of the intestinal tract caused by protozoan organisms in the genus Eimeria. These obligate intracellular parasites have complex life cycles that include both sexual and asexual reproductive phases within the epithelial cells lining the intestinal wall. Each Eimeria species is highly host-specific - the species that infect cattle cannot infect poultry, and vice versa - and each species tends to colonize a particular region of the intestinal tract. The pathology of coccidiosis results from the physical destruction of intestinal epithelial cells as the parasites multiply within them, and the severity of disease correlates directly with the number of oocysts ingested, the pathogenicity of the infecting species, and the immune status of the host.

The life cycle of Eimeria begins when an animal ingests sporulated oocysts from the environment. These oocysts are remarkably durable structures that can survive for months in soil, bedding, and on contaminated surfaces. Once ingested, the oocyst wall is dissolved by digestive enzymes, releasing sporozoites that invade intestinal epithelial cells. Within these cells, the parasites undergo multiple rounds of asexual reproduction called schizogony, during which each infected cell produces dozens to hundreds of daughter organisms called merozoites. These merozoites burst out of the host cell, destroying it in the process, and invade new epithelial cells to repeat the cycle. After two or three generations of schizogony, the parasites enter a sexual reproductive phase that produces new oocysts, which are shed in the feces and contaminate the environment to perpetuate the cycle. The massive cellular destruction during schizogony is what produces the clinical signs of coccidiosis: diarrhea, intestinal hemorrhage, dehydration, weight loss, and in severe cases, death.

In cattle, clinical coccidiosis most commonly affects calves between three weeks and six months of age, though animals up to two years old can develop disease under heavy exposure conditions. The hallmark clinical sign is diarrhea that progresses from watery to bloody as intestinal damage worsens, earning the common name bloody scours. Affected calves are depressed, dehydrated, and may strain excessively during defecation. Even animals that recover from acute clinical coccidiosis often suffer lasting damage to the intestinal lining that impairs nutrient absorption and reduces growth performance for weeks or months after the clinical episode resolves. The subclinical form of bovine coccidiosis - infection without overt bloody diarrhea - is economically significant because it reduces feed efficiency and daily weight gain in feedlot cattle without producing obvious signs that would prompt treatment.

In poultry, coccidiosis manifests differently depending on the Eimeria species involved and the region of the intestine affected. Eimeria tenella targets the ceca and produces the classic bloody cecal coccidiosis with high mortality in young chicks. E. necatrix invades the mid-intestine and causes severe hemorrhagic enteritis. E. acervulina affects the upper small intestine and produces white streaks or plaques visible on the mucosal surface. Mixed infections with multiple Eimeria species are common in commercial flocks and can produce additive or synergistic pathology. Coccidiosis remains one of the most economically significant diseases in the global poultry industry, with estimated annual costs exceeding several billion dollars worldwide when losses from mortality, morbidity, treatment costs, and subclinical production impacts are combined.

Proper storage and handling of amprolium products ensures that the drug retains its potency and is administered safely throughout the treatment or prevention program. The 9.6% oral solution should be stored at controlled room temperature, protected from freezing and excessive heat. The bottle should be shaken well before each use to resuspend any settled particles and ensure uniform drug concentration throughout the solution. The 20% soluble powder should be kept in its original sealed container in a cool, dry location, protected from moisture that could cause caking and reduce solubility. The 1.25% crumble formulation should be stored in sealed bags or containers away from moisture and direct sunlight. All amprolium products should be kept out of reach of children, and handlers should avoid contact with eyes and skin during preparation and administration.

Medicated drinking water prepared with amprolium must be mixed fresh daily. Amprolium solutions left standing for more than 24 hours may lose potency and should be discarded. When treating groups of animals through communal water sources, producers must ensure that the medicated water is the only water available to the animals being treated. Access to alternative water sources - puddles, streams, leaking waterers in adjacent pens - allows animals to dilute their intake of medicated water and receive subtherapeutic doses that are insufficient to control coccidiosis and may promote the development of tolerance in the parasite population. For drenching individual animals, the drench solution should be prepared fresh for each treatment session and administered carefully to avoid aspiration.

Practical considerations for effective coccidiosis management extend beyond drug administration to encompass environmental sanitation, stocking density, and stress reduction. Amprolium treats the disease but does not address the environmental contamination that sustains the cycle of reinfection. Cleaning and disinfecting pens, coops, and feeding equipment reduces the oocyst burden in the environment, while managing stocking density prevents the fecal contamination levels from overwhelming the protective capacity of treatment or immunity. Stress factors such as weaning, transport, dietary changes, temperature extremes, and overcrowding all suppress immune function and increase susceptibility to coccidiosis, making stress management an integral companion to pharmaceutical intervention.

Record keeping is an important practical aspect of amprolium use, particularly for producers selling animals or animal products for human consumption. Treatment records should document the product used, the concentration prepared, the dates of treatment, the animals treated, and the calculated withdrawal date. For extra-label uses, records should additionally document the prescribing veterinarian's instructions and the extended withdrawal period applied. These records are required under federal regulations for food-producing animals and demonstrate compliance with food safety standards in the event of a regulatory inspection or residue detection incident. Maintaining organized treatment records also helps producers track coccidiosis patterns in their herds or flocks over time, identify seasonal or management-related risk factors, and refine their prevention strategies accordingly.

Producers frequently ask whether amprolium is an antibiotic, and the answer is definitively no. Amprolium is a thiamine analogue that targets the metabolic pathways of Eimeria protozoa and has no activity against bacteria. It does not contribute to antibiotic resistance, does not disrupt the beneficial intestinal microbiota, and is not subject to the regulatory restrictions that apply to antibiotic use in food-producing animals. This distinction is practically important because it means amprolium can be used in production systems marketed as antibiotic-free or raised without antibiotics without compromising those claims.

Another common question concerns whether amprolium can be used simultaneously with other medications. In general, amprolium is compatible with most other drugs, vaccines, and feed additives commonly used in livestock and poultry production. The critical exception is supplemental thiamine or vitamin B1, which must be withheld during active amprolium treatment because it directly counteracts the drug's anticoccidial mechanism. Standard vitamin premixes that include B-complex vitamins should be removed from the feed during the treatment period. After the treatment course is completed, thiamine supplementation can be resumed and is in fact recommended by many veterinarians to replenish any thiamine stores that may have been marginally depleted during treatment, particularly after extended prevention protocols.

Producers managing mixed-species operations often ask whether the same amprolium solution can be used for multiple species simultaneously. While the active ingredient is the same regardless of species, the labeled concentrations and treatment durations differ between cattle and poultry formulations, and extra-label use in goats, sheep, and rabbits requires species-appropriate dosing under veterinary direction. Using a product labeled for one species in another species constitutes extra-label use and requires a valid veterinarian-client-patient relationship. Water medication systems shared between species must be calibrated to deliver the correct concentration for the species being treated, and treatment records should reflect the specific dosing protocol applied to each group.

The question of whether coccidiosis can be cured permanently with a single course of amprolium reflects a misunderstanding of the relationship between the parasite, the host, and the environment. Amprolium controls the clinical consequences of a coccidial infection, but it does not eliminate Eimeria from the environment or confer permanent immunity through treatment alone. Animals may be reinfected after treatment if they return to contaminated environments without having developed adequate immunity. Effective long-term coccidiosis control requires an integrated approach combining strategic use of amprolium during high-risk periods, environmental sanitation to reduce oocyst loads, management practices that minimize stress and overcrowding, and allowing controlled exposure to build natural immunity in young animals. Producers who view amprolium as one component of a comprehensive management strategy rather than a standalone cure achieve the most consistent and durable results.